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A stability-indicating high-performance thin-layer chromatographic (HPTLC) method for determination of tenofovir disoproxil
fumarate in bulk drug and in tablet has been developed and validated. The mobile phase selected was chloroform:methanol
(9.0:1.0, v/v) with ultraviolet (UV) detection at 260nm. The retention factor was found to be 0.49±0.03 with correlation
coeﬃcients of 0.9994 in the range 300–1500ng/spot and with an accuracy of 99.25%. Method had the potential to determine
tenofovir disoproxil fumarate from tablet without any interference, and it was a stability-indicating one.
1.Introduction
The aim of the present study was to establish the inherent
stability of tenofovir disoproxil fumarate through stress
studies under a variety of International Conference on Har-
monisation (ICH) recommended test [1–3]a n dt od e v e l o pa
stability-indicating assay [4–6].
Tenofovir is converted intracellularly to the diphosphate.
This diphosphate halts the DNA synthesis of HIV through
competitive inhibition of reverse transcriptase and incor-
poration into viral DNA. It also inhibits hepatitis B virus
polymerase, resulting in inhibition of viral replication. It is
used in the treatment of HIV infection and chronic hepatitis
B infection.
Chemically tenofovir disoproxil Fumarate (TDF) is
fumaric acid salt of the bisisopropoxycarbonyloxymethyl
ester derivative of tenofovir. Chemically, it is 9-[(R)-2-
[[bis[[(isopropoxycarbonyl)oxy]methoxy]phosphinyl]
methoxy]propyl]adenine fumarate (Figure 1(a)). It is not
oﬃcial in any of the pharmacopoeias. This is listed in the
Merck Index and Martindale: The complete drug reference
[7, 8]. Literature review reveals that several methods have
been reported for the estimation of TDF in tablets [9–11],
high-performance liquid chromatographic methods [12–
16], liquid chromatography-mass spectrometry [17–21],
and high-performance thin-layer liquid chromatographic
methods (HPTLCs) [22].
An ideal stability-indicating method shall quantify the
drug per se and also resolve its degradation products.
Thin-layer chromatography has become a part of routine
analytical techniques in many product development and
analytical laboratories due to its advantages [23–25]. So
far, to our present knowledge, no stability-indicating high-
performance thin-layer chromatography assay method for
the determination of TDF is available in the literature. It
was felt necessary to develop a stability-indicating HPTLC
method for the determination of TDF as bulk drug and
pharmaceutical dosage form and separate the drugs from the
degradation products under the ICH-suggested conditions
[26].
2. Experimental
2.1. Chemical and Reagents. Pharmaceutical grade TDF
(batch no. 481372) working standard was obtained as gener-
ousgiftsfromRanbaxyPvt.Ltd.,Indore,India.Commercial-
ly available Tentide tablets (300mg) [T-I] were purchased
from Ranbaxy Pvt. Ltd., India and Tavin (300mg) [T-II]
from Emcure pharmaceuticals. All chemicals and reagents
were of analytical-grade and were purchased from Merck
Chemicals, Mumbai, India.2 The Scientiﬁc World Journal
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Figure 1: (a) Chemical structure of tenofovir disoproxil fumarate.
(b) Representative chromatogram obtained for the placebo.
2.2. Instrumentation
2.2.1.ForStressStudy. High-precisionheatingmantel(Remi,
India) capable of controlling the temperature within ±1◦C
was used for generating hydrolytic degradation products.
The thermal degradation study was performed using a high-
precisionhot-airoven(KumarScientiﬁcWorks,Pune,India)
capable of controlling the temperature with in ±2◦C. Photo-
degradation was carried out in a photostability chamber
(Thermolab, Scientiﬁc Equipment Pvt Ltd.) equipped with
lighting system to comply with ICH guideline for pho-
tostability condition with white ﬂourescent light exposure
for 1.2 million lux hours and integrated near-ultraviolet
energy exposure of 200 watts hours/sq·mts (option 2 of the
ICH guideline Q1B). At any given time, UV energy and
visible illumination were tested using a calibrated lux meter
(Lutron, LX-101A).
2.2.2. Chromatography. The HPTLC system consisted of a
Camag Linomat 5 semiautomatic spotting device (Camag,
Muttenz, Switzerland), a Camag twin-trough chamber
(10cm × 10cm), Camag winCATS software 1.4.4.6337, and
a 100μL Hamilton syringe. Sample application was done on
precoated silica gel 60 F254 TLC plates (10cm × 10cm). TLC
plates were prewashed with methanol and activated at 80◦C
for 5min prior to the sample application. Densitometric
analysis was carried out utilizing Camag TLC scanner 3.
2.3.PreparationofStandardStockSolutions. Astandardstock
solution of concentration 1mg/mL of TDF was prepared
in actonitrile. Working standard solutions were prepared by
serial dilution of the stock solution with the mobile phase.
2.4. General Assay Procedure
2.4.1. Preparation of the Calibration Graph. Working stan-
dard solutions containing 300–1500ng/spot of TDF were
prepared by serial dilution of aliquots of the stock solution.
Each concentration was applied six times on the TLC
plate and the peak areas of TDF were plotted against
the corresponding concentration (ng/spot) to obtain the
calibration graph.
2.4.2. Analysis of Bulk Substance. The method mentioned
above was applied for the determination of the purity of
TDF raw material. The percentage recoveries were calculated
by referring to the calibration graph previously prepared or
applying the regression equation.
2.4.3. Procedure for Stress Testing. A stock solution contain-
ing 100mg TDF in 100mL acetonitrile was prepared. This
solution was used for forced degradation to provide an
indication of the stability-indicating ability and speciﬁcity
of the proposed method. In all degradation studies, the
average peak areas of TDF (150ng/spot) were obtained after
application of 6 replicates.
(a) Hydrolysis. 5mL of a standard stock solution (1mg/mL)
was mixed with 5mL 0.01M HCl at room temperature. The
alkaline hydrolysis was carried out by mixing a standard
stock solution 5mL (1mg/mL) with 0.01M NaOH (5mL)
kept at room temperature. The solution was then neutralized
with 0.01M NaOH and 0.01M HCl for the acidic and
alkaline degradation, respectively.
(b) Oxidation. For the purpose of oxidation studies a
mixture of 5mL standard stock solution and 5mL hydrogen
peroxide (0.3%, v/v) was kept at room temperature and
then heated in a boiling water bath for 10min to completely
remove the excess hydrogen peroxide.
(c) Dry Heat Degradation. 10mg standard drug as powder
w a sp l a c e di na no v e na t5 0 ◦C for 2 months to study dry-heat
degradation.
(d) Photochemical Degradation. Photodegradation studies
were carried out according to Option 2 of Q1B in ICH
guidelines. The stock solution (1mg/mL) as well as solid
drug was exposed to light for an overall illumination of 1.2
million lux/h and an integrated near ultraviolet energy of
200Whm−2 for 8hrs.
(e) Neutral Hydrolysis. To study the degradation behavior of
drug in neutral conditions, 5mL of a standard stock solutionThe Scientiﬁc World Journal 3
(1mg/mL) was mixed with 5mL double-distilled water and
heated at 80◦C for 5 days, and subsequently for 10 days.
2.4.4. Analysis of Dosage Forms. For the analysis of tablets, 20
tablets of each batch T-I and T-II were weighed and ﬁnely
ground in a mortar. For T-I and T-II, the portion equivalent
to 300mg of TDF was transferred in a 50mL volumetric
ﬂask, 35mL of acetonitrile was then added, and sonication
was done for 45min with swirling. After sonication, the
volume was made up to the mark with the acetonitrile and
mixedwell.ThesolutionwasﬁlteredthroughWhatmanﬁlter
paper 41.
For both T-I and T-II, six determinations were per-
formed.
2.5. Optimization of the Stability-Indicating HPTLC Method.
HPTLC method was optimized to establish a stability-
indicatingassay.Bothpureanddegradeddrugsolutionswere
applied to HPTLC plates chromatographed with diﬀerent
mobile phases.
2.6. Analytical Method Validation. The developed HPTLC
method was validated for linearity, precision, accuracy,
sensitivity, robustness, and system suitability.
2.6.1. Linearity and Range. Accurate quantities from stan-
dard solutions were applied on the TLC plate to furnish
bands containing 300–1500ng/spot of TDF. Each amount
was applied six times to the plate. The plate was developed in
optimized mobile phase and scanned. As it was reported, the
correlation coeﬃcient alone is not suitable to prove linearity
[27]. So residual plot was generated.
2.6.2. Precision. The precision of the method was veriﬁed
by repeatability and intermediate precision studies at a con-
centration level of 300, 900, and 1500ng/spot. Repeatability
studieswereperformedbysixtimesanalysisonthesameday.
The intermediate precision of the method was checked by
repeating studies on three diﬀerent days.
2.6.3. Sensitivity. Sensitivity was determined by establishing
the limit of detection (LOD) and limit of quantitation
(LOQ). LOD and LOQ were calculated as 3.3 and 10 σ/S,
respectively, where σ was the standard deviation of the
response (y-intercept) and S was the slope of the calibration
curve obtained by injecting a series of dilute solutions with
known concentration.
2.6.4. Robustness and System Suitability. Following the
introduction of small changes in the optimized mobile
phase composition (±0.1mL for each component), mobile
phases having diﬀerent compositions, for example, chlo-
roform:methanol (8.9:1.0v/v), (9.1:1.0v/v), (9.0:0.9v/v),
(9.0:1.1v/v) were tried and densitogram was run. The
amount of mobile phase was varied over the range of ±0.1%.
The plates were prewashed by methanol and activated at
110◦C for 4, 5, 6min, respectively, prior to chromatog-
raphy. Time from spotting to chromatography and from
chromatography to scanning was varied from +10min.
Robustness of the method was done at a concentration level
of 400ng per band.
2.6.5. Speciﬁcity. Tablet matrix without drug components
and tablet matrix spiked with drug components were
prepared in acetonitrile. The solution of tablet matrix
without drug components was made with high-excipient
concentration to enable detection of any excipient spots with
similar Rf values as the drug components. Spiking of tablets
matrix was performed to make a solution with 300, 900, and
1500ng/spot.
2.6.6. Accuracy. Accuracy of the method was tested by
applying the method to drug sample to which known
amounts of TDF standard powder corresponding to 80, 100,
and 120% of label claim had been added (standard addition
method), mixed, and the powder was extracted and analyzed
by running chromatograms in optimized mobile phase.
These mixtures were analyzed by the proposed method. The
experimentwasperformedintriplicateandrecovery(%)was
calculated.
2.6.7. Analysis of Marketed Formulation. T h ec o n t e n t so f
drug in tablets were determined by the proposed method
using the calibration curve.
2.6.8. Solution Stability. The solution stability of TDF was
carriedoutbyleavingthetestsolutionintightlycappedvolu-
metric ﬂasks at room temperature for 24h and assayed at 6h
interval against the freshly prepared standard solution. The
%RSD of assay of TDF was calculated for the study period
during mobile phase and solution stability experiments.
3. Results and Discussion
3.1. Method Development and Optimization. Diﬀerent pro-
portions of acetone, toluene, methanol, and chloroform
were tried for selection of mobile phase. Ultimately, chlo-
roform:methanol (9.0:1.0v/v) was found to be optimum
(Figure 2)a tRf 0.49 ± 0.03. In order to reduce the necklace
eﬀect, TLC chamber was saturated for 30min using satura-
tionpads.Themobilephasewasrunuptoadistanceof8cm;
whichtakesapproximately20minforcompletedevelopment
of the TLC plate and scanning wavelength was 260.
3.2. Detection of Degradation Products by HPTLC
3.2.1. Hydrolysis. Acid and alkaline degradation of TDF was
performedin1:1acetonitrile—0.01MHClandNaOH.TDF
washighlysusceptibletoattackbyHClandNaOH.Complete
degradation occurred immediately after addition of HCl and
NaOH at room temperature.4 The Scientiﬁc World Journal
Table 1: Precision of HPTLC methoda.
Compound
Repeatability Intermediate
Mean% assay %RSD Mean% assay %RSD
TDF 100.30 1.05 100.61 1.26
an = 6, (300, 900, 1500ng/spot).
Table 2: Robustness testinga.
Parameters SD of peak area %RSD
Mobile phase composition
(±0.1mL) 29.19 1.12
Amount of mobile phase (±5%) 15.22 1.01
Plate pretreatment (4, 5, 6min) 9.51 0.07
Time from spotting to
chromatography (+10min) 2.03 0.03
Time from chromatography to
scanning (+10min) 0.73 0.05
an = 6.
Table 3: Stability of drug in sample solutiona.
Time of analysis (h) SD %RSD
6 9.37 0.22
12 9.02 0.38
18 8.93 0.01
24 8.62 0.72
a(n = 6).
3.2.2. Oxidation. T h ed r u gw a sf o u n dt ob eu n s t a b l et o
oxidative degradation. In 1:1 acetonitrile, 0.3% H2O2 com-
plete degradation occurs immediately at room temperature.
3.2.3. Dry Heat Degradation Product. There was no signif-
icant degradation of solid TDF on exposure to dry heat at
50◦C for 2 months, which indicated that drug was stable
against thermal stress.
3.2.4. Photolysis. TDF was degraded in photochemical
degradation after exposing drug to a combination of white
ﬂuorescent and integrated near-ultraviolet energy at 1.2
million lux hours and 200 watts hours/sq·mts, respectively,
for 8h forming two major degradation products at 0.58 and
0.72 (Figure 3).
3.2.5. Neutral Degradation. TDF under neutral hydrolysis
did not give rise to the presence of degradants as the peak
area remained constant which indicated drug stability under
the conditions investigated.
3.3. Validation
3.3.1. Linearity. Good linearity was observed in the con-
centration range of 300–1500ng/spot of TDF. The data was
subjected to statistical analysis using a linear regression
model; the result shows that, within the concentration
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Figure 2: Densitogram of standard tenofovir disoproxil fumarate
100ng/spot; Peak 1 (Rf:0 . 4 9± 0.03), mobile phase-chloroform:
methanol (9.0:1.0 v/v).
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Figure 3: Densitogram of the photodegradation product
150ng/spot;condition: white ﬂuorescent andintegrated near-ultra-
violet energy at 1.2 million lux hours and 200 watts hours/sq·mts
for 8h; Peak 1 (tenofovir disoproxil fumarate, Rf:0.50), Peak 2
(degraded, Rf:0.58), and Peak 3 (degraded, Rf:0.72).
range mentioned above, there was an excellent correlation
between peak areas, and concentrations of drug intercept
and slope were found to be 13.37 and 5.70, respectively, with
correlation coeﬃcient of 0.999. The relationship between the
concentration of each of TDF and peak area of the spot was
investigated. The linear relationship was tested and found to
be linear, indicating good correlation (Figure 4).The Scientiﬁc World Journal 5
Table 4: Recovery studiesa.
Label claim Amount of drug added (%) Total amount of drug
present μg/mL Amount found μg/mL %R e c o v e r y±
SD
T-I
300mg
80 10800 10733.04 99.38 ±0.82
100 12000 11941.2 99.51 ±0.23
120 13200 13101 99.25 ±0.63
T-II
300mg
80 10800 10725.48 99.31 ±0.22
100 12000 11980.8 99.84 ±0.30
120 13200 13082.52 99.11 ±0.75
an = 6.
3.3.2. Precision. Precision was evaluated by carrying out six
independent sample preparations of a single lot of formu-
lation. Percentage relative standard deviation (%RSD) was
found to be less than 2% for repeatability and intermediate
variations as shown in Table 1.
3.3.3. LOD and LOQ. The LOD and LOQ values were found
to be 8 and 25ng/spot.
3.3.4. Speciﬁcity. The densitogram of the solution of the
nonspikedtabletmatrixdidnotshowanyspots.Ontheother
hand, the densitogram of the solution of tablet matrix spiked
with TDF showed clear, compact spot. Moreover, no other
spots eluted besides the active compounds. Therefore, the
method was considered speciﬁc (Figure 1(b)).
3.3.5. Robustness of the Method. T h er o b u s t n e s so ft h e
method was determined by variations in mobile phase
composition (±0.1mL for each component), amount of
mobilephase(±1%),timefromspottingtochromatography,
and from chromatography to scanning (+10min). One
factor at a time was changed at a concentration level of
400ng/spot, to study the eﬀect on the peak area of the drugs.
The method was found to be unaﬀected by small changes
with %RSD for all the parameters less than 2%, indicating
that the method is robust shown in Table 2.
3.3.6. Solution Stability Study. No additional peak was found
in the densitogram of sample from solution stability. The
results from solution-stability and mobile-phase-stability
experimentsconﬁrmedthatstandardsolutionsandsolutions
in the mobile phase were stable up to 24h for assay and
related substances analysis as shown in Table 3.
3.3.7. Recovery Studies. Good recoveries of the TDF were
obtained at various added concentrations for T-I and T-II as
shown in Table 4.
2.6.4.RobustnessandSystemSuitability. Experimentalresults
of the amount of TDF in tablets, expressed as a percentage of
label claims, were in good agreement with the label claims
thereby suggesting that there is no interference from any
Table 5: Applicability of the HPTLC method for the analysis of the
pharmaceutical formulations.
Label claim (mg) Sample Drug Content
(%) %RSD
300 T-I 99.13 1.03
T-II 99.37 0.84
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Linear regression of teno HPTLC: residuals
Figure 4: Residual plot of tenofovir disoproxil fumarate.
of the excipients which are normally present in tablets.
Two diﬀerent brands of ﬁxed dose combination tablets were
analyzed using the proposed procedures as shown in Table 5.
4. Conclusion
This study showed that tenofovir disoproxil fumarate was
found to be unstable under acidic, alkaline, and oxidative
conditions as it degradaed completely, but it was found that
it is labile to photolysis and that complete separation of
degradants was carried out using stability-indicating HPTLC
method. Tenofovir disoproxil fumarate was observed to be
stable when exposed to neutral condition and dry heat. The
d e v e l o p e dH P T L Cm e t h o dp r o v e dt ob es i m p l e ,a c c u r a t e ,
precise, andspeciﬁc. Hence,it is recommendedforindustrial
analysis of drug and degradation products obtained from
stability procedures.6 The Scientiﬁc World Journal
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